SlideShare a Scribd company logo
1 of 40
Download to read offline
Update on the
New ACC/AHA
Guideline on
the Treatment
of Blood
Cholesterol to
Reduce
Atherosclerotic
Cardiovascular
Risk in Adults
Terry Shaneyfelt, MD, MPH
Gen Med Noon Conf.
December 10, 2013
Disclosures
o > 5yrs ago speaker for unrestricted
educational grant to Johns Hopkins School of
Medicine on cholesterol mgmt and EBM
• Funded by AstraZeneca (Rosuvastatin)

o VA P&T Committee member
Objectives
o Apply the new guidelines to the care of adults
at increased risk for ASCVD
o Understand limitations of new pooled cohort
risk prediction tool

o Learn a little something about guideline
limitations and prediction rules
Review of the New ACC/AHA Cholesterol Guidelines
Clinical practice guidelines are statements
that include recommendations intended to
optimize patient care that are informed by a
systematic review of evidence and an
assessment of the benefits and harms of
alternative care options
-- Institute of Medicine 2011
To be trustworthy guidelines must:
o Be based on a systematic review of the existing evidence;

o Be developed by a knowledgeable, multidisciplinary panel of experts and
representatives from key affected groups;
o Consider important patient subgroups and patient preferences, as appropriate;
o Be based on an explicit and transparent process that minimizes distortions, biases, and
conflicts of interest;
o Provide a clear explanation of the logical relationships between alternative care options
and health outcomes,

o Provide ratings of both the quality of evidence and the strength of the
recommendations; and
o Be reconsidered and revised as appropriate when important new evidence warrants
modifications of recommendations.
IOM 2011
o No LDL target
o Statins only
o Only considered high quality RCT data
Review of the New ACC/AHA Cholesterol Guidelines
o ACS, h/o
MI, angina, revascularization, TIA, stroke, peri
pheral arterial disease
o No RCTs identified that titrated drug therapy
to specific LDL goals to improve ASCVD
outcomes
Review of the New ACC/AHA Cholesterol Guidelines
o Often genetic (family screening)
o Consider secondary causes
– Drugs
(diuretics, cyclosporin, glucocorticoids, amiodaron
e)
– Biliary obstruction, nephrotic syndrome
– Hypothyroidism, pregnancy*
* Statins contraindicated in pregnancy & lactation
o Extrapolation of data for primary prevention
in high risk (≥ 7.5% 10 yr risk) who did not
have diabetes
– Expert opinion, some conflicting data (IIa, B)

o < 40 or > 75 yrs the decision to initiate statin
therapy should be individualized
– Expert opinion, divergent opinions (IIa, C)
o Most controversial area of guideline because of
risk equations & lower cut off
o Reasonable to offer statin therapy to those with
risk of 5-7.5% [conflicting evidence (IIa, B)]
Primary Prevention

JAMA 11/25/13

o Healthy individuals aged 40-75 yrs., without
serious comorbidities and who were not taking
drugs with potential for statin interaction
Primary Prevention
o CTT metaanalysis (Lancet 2012;380:581)
– Similar efficacy findings
– found increased risk of myopathy (NNH
2000), diabetes (NNH 200) and hemorrhagic
stroke (NNH 2000)
– No reduction in CVD events in patients with
• Heart failure
• Maintenance hemodialysis
Lancet 2012;380:581

1 mmol/l = 38.6 mg/dl
o Conflicts of interest in most panel members
o Increased in statin utilization (“statinization”)?
Conflicts of Interest
o 2 main types
– Financial
– Intellectual

o Per IOM 2011:
– Whenever possible GDG members should not have COIs.
– Members with COIs should represent not more than a
minority of the GDG.
– The chair or co-chairs should not be a person(s) with COIs.
– Funders should have no role in CPG development.
Conflicts of Interest
o COI should be disclosed
• Disclosure should reflect all current and planned commercial
(including services from which a clinician derives a substantial
proportion of income), noncommercial, intellectual, institutional, and patient– public
activities pertinent to the potential scope of the CPG.

o Members of the GDG should divest themselves of
financial investments they or their family
members have in, and not participate in marketing
activities or advisory boards of, entities whose
interests could be affected by CPG
recommendations
“Majority of panelists on controversial new cholesterol
guideline have current or recent ties to drug manufacturers”
- BMJ 2013;347:16989

o Neil Stone, MD (chairman)
• Abbott, AstraZeneca, Merck, Pfizer, Sanofi-Aventis and
Schering-Plough
• “I will not take industry funding for 2 years after release
of the guidelines”

o Jennifer Robinson, MD (Co-chair)
• Financial ties to several statin manufactures while on
panel from 2008-2013

o 6 of 8 panelist with financial ties during
service on the panel!
Conflicts of Interest
o “Members with conflicts were asked to recuse
themselves from voting on any aspect of the
guideline where a conflict might exist”

o Independent contractors performed the
systematic review of evidence
Increased in statin utilization
(“statinization”)?
o Risk calculator overestimates risk
o Lower thresholds to initiate statin therapy

o 101 million people in US aged 40-79 yrs
without cardiovascular disease
• 33 million expected to have ≥ 7.5% predicted risk
• 13 million expected to have 5-7.4% predicted risk
• US population 1/20th global population in this age range
– (33+13) x 20 = 920 million worldwide would be new statin
candidates (JAMA 12/2/13)
Is this a bad thing?
MI and stroke are leading
causes of death in the US

Health Affairs 2012
o Risk prediction tool overestimates risk
Clinical prediction rule development

Step 2. Validation
Evidence of reproducible accuracy

Step 1. Derivation
Identification of factors with
predictive power

Narrow Validation
Application of a rule
in a similar clinical
setting and population
as in Step 1

Broad Validation
Application of a rule
in multiple clinical
settings with varying
prevalence of disease

Step 3. Impact
Analysis
Evidence that rule changes
physician behavior and
improves patient outcomes
Why a new risk predictor?
o Previously used Framingham risk score was not felt to be
adequate because of its “derivation in an exclusively White
sample population and the limited scope of the outcome (in
determining CHD alone).”
o Other risk scores also suffered from “nonrepresentative or historically
dated populations, limited ethnic diversity, narrowly defined
endpoints, endpoints influenced by provider preferences
(e.g., revascularizations), and endpoints with poor reliability
(e.g., angina and heart failure [HF]).”

o Broader outcomes of interest
• ASCVD: first occurrence of nonfatal myocardial infarction
or CHD death, or fatal or nonfatal stroke
Review of the New ACC/AHA Cholesterol Guidelines
Development of the Pooled Cohort
Risk Assessment Equations
– Used several large, racially and
geographically diverse, modern
NHLBI-sponsored cohort
studies, including the ARIC
study, Cardiovascular Health
Study, and the CARDIA
study, combined with applicable
data from the Framingham
Original and Offspring Study
cohorts
– Sex-and race-specific
proportional hazards models that
included the covariates of
age, treated or untreated systolic
blood pressure (SBP), total
cholesterol, high-density
lipoprotein cholesterol (HDLC), current smoking (Y/N), and
diabetes (Y/N).

– Calculated area under the
receiver operating curve (Cstatistic) for discrimination and
the calibration chi-squared
statistic
– External validation done in
external cohorts consisting of
Whites and African Americans
from the Multi-Ethnic Study of
Atherosclerosis (MESA) and the
REasons for Geographic And
Racial Differences in Stroke study
(REGARDS) and contemporary
cohorts from ARIC and
Framingham.
Validation
o Discrimination
– Accurately determine if a person has or doesn’t
have disease
– C-statistic or AUC

o Calibration
– How well do predicted risk estimates match
observed risk in external populations
Validation

(http://circ.ahajournals.org/content/early/2013/11/11/01.cir.0000437741.48606.98/suppl/DC1 )
Wom en
Algorithm
Derivation
Cohort

Men

Validation Cohorts
Contemporary
(4)

MESA
(5)

Validation Cohorts

Algorithm

REGARDS
(6)

Derivation
Cohort

Contemporary
(4)

MESA
(5)

REGARDS
(6)

White
Total N

11,240

6,509

1,273

6,333

9,098

5,041

1,184

5,296

Events(1)

683

400

37

101

1,032

539

57

218

Events(2)

722.9

426.7

38.4

120.7

1,095.2

580.9

59.7

250.2

Exp
Events(3)

723.5

549.4

49.9

153.9

1,098.5

798.9

94.9

306.4

0.8058

0.7377

0.7109

0.6599

0.7462

0.6843

0.7044

0.5950

6.43

45.50

14.56

44.93

4.86

84.45

21.43

66.71

2,641

1,367

978

5,275

1,647

735

799

2,969

Events(1)

235

127

28

126

194

107

36

136

Events(2)

248.7

131.3

30.1

147.1

213.8

114.0

38.3

162.5

Exp
Events(3)

250.6

173.5

59.4

217.5

212.5

120.8

72.3

180.7

0.8182

0.7068

0.7684

0.6625

0.7130

0.7109

0.6689

0.5564

7.25

15.96

18.51

48.22

6.71

12.62

24.40

46.23

Cstatistic
Calib.
Chi-sq
African
Am erican
Total N

Cstatistic
Calib.
Chi-sq

C statistic: range 0.5 – 1.0 (“reasonable” > 0.7, “strong” > 0.8)
Calibration
External Validation

The Lancet, Volume 382, Issue 9907, Pages 1762 - 1765

o How many of the 33 million expected to have
risk >7.5% actually have risk that is much
lower?
What should you do about risk
assessment?
o Use the pooled risk estimation equations
o Use other risk scores (eg Framingham, QRISK, etc)
o Ignore any risk assessment and consider that
almost everyone benefits from primary
prevention
o Use eligibility criteria of the primary prevention
trials
Other recommendations from the
guidelines
o In lower risk patients (5-7.5%, < 40 or > 75 yrs)
clinicians should discuss with patients:
•
•
•
•

ASCVD risk reduction benefits (30% RRR MIS, 45% HIS)
Adverse effects (diabetes NNH 200)
Drug-drug interactions
Patient preferences

o In lower risk individuals also consider:
• FH of premature CAD (< 55yo M, < 65yo F)
• hsCRP > 2
• CAC score >300 Agatston units (or >75 percentile for
age)
Other recommendations from the
guidelines
o CK should not be routinely measured
o Measure baseline ALT and only remeasure if
symptoms suggest hepatotoxicity
o Screen for diabetes following current diabetes
screening guidelines
o Muscle symptoms:
• Temporarily d/c statin and assess for rhabdo if severe &
other conditions that cause muscle symptoms
• Rechallenge with lower or same dose of statin
– If statin causative then give lower dose of different statin
Other recommendations from the
guidelines
o No recommendations for add-on therapy to
lower LDL after optimal statin dosing
o Separate guideline on triglycerides (Circul 2012)
• No gemfibrozil
• Fenofibrate only if TG > 500 mg/dl and benefits judged to
outweigh risks

o Consider rechecking lipid panel 4-12 wks after
initiation to assess for adherence but not to
adjust therapy
Review of the New ACC/AHA Cholesterol Guidelines
Review of the New ACC/AHA Cholesterol Guidelines
Suggested Answers
o Case 1: B
• Pt has ASCVD and should be on high intensity statin

o Case 2: A or B
• Risk is estimated at 7.2% which is below absolute
recommended cutoff to initiate statin therapy for primary
prevention

o Case 3: E (if not tolerated then D)
• Risk is estimated at 9.1% (driven by age) which is above the
7.5% threshold.
By Brian McFadden at DailyKos.com

More Related Content

What's hot

DELIVER delivered 2022.pptx
DELIVER delivered 2022.pptxDELIVER delivered 2022.pptx
DELIVER delivered 2022.pptxhospital
 
Diabetic Dyslipidemia - A True CV risk
Diabetic Dyslipidemia - A True CV riskDiabetic Dyslipidemia - A True CV risk
Diabetic Dyslipidemia - A True CV riskUsama Ragab
 
DYSLIPIDEMIA GUIDELINES
DYSLIPIDEMIA GUIDELINESDYSLIPIDEMIA GUIDELINES
DYSLIPIDEMIA GUIDELINESarnab ghosh
 
Crestor Presentation
Crestor PresentationCrestor Presentation
Crestor Presentationhospital
 
Antiplatelet therapy
Antiplatelet therapyAntiplatelet therapy
Antiplatelet therapyArindam Pande
 
Summary of PROVE-HF and GUIDE-IT studies by Dr. Vaibhav Yawalkar MD, DM Cardi...
Summary of PROVE-HF and GUIDE-IT studies by Dr. Vaibhav Yawalkar MD, DM Cardi...Summary of PROVE-HF and GUIDE-IT studies by Dr. Vaibhav Yawalkar MD, DM Cardi...
Summary of PROVE-HF and GUIDE-IT studies by Dr. Vaibhav Yawalkar MD, DM Cardi...vaibhavyawalkar
 
Lipid lowering trials ppt
Lipid lowering trials pptLipid lowering trials ppt
Lipid lowering trials pptNavin Agrawal
 
Management of Dyslipidemia: role of Fenofibrate
Management of Dyslipidemia: role of FenofibrateManagement of Dyslipidemia: role of Fenofibrate
Management of Dyslipidemia: role of FenofibrateVinh Pham Nguyen
 
New Treatments in HFrEF
New Treatments in HFrEFNew Treatments in HFrEF
New Treatments in HFrEFDuke Heart
 
ACC/AHA lipid guidelines 2018
ACC/AHA lipid guidelines 2018ACC/AHA lipid guidelines 2018
ACC/AHA lipid guidelines 2018Mgfamiliar Net
 
145pm-THREE-MAJOR-TRIALS-acc-2023.pdf
145pm-THREE-MAJOR-TRIALS-acc-2023.pdf145pm-THREE-MAJOR-TRIALS-acc-2023.pdf
145pm-THREE-MAJOR-TRIALS-acc-2023.pdfMoniraKhatunMoni
 
Diabetic dyslipidemia
Diabetic dyslipidemiaDiabetic dyslipidemia
Diabetic dyslipidemiaFarragBahbah
 
Dyslipidemia GL & Total Vascular Benefit .pptx
Dyslipidemia GL & Total Vascular Benefit .pptxDyslipidemia GL & Total Vascular Benefit .pptx
Dyslipidemia GL & Total Vascular Benefit .pptxWidiHadian3
 
Management of dyslipidemia 2019 update
Management of dyslipidemia  2019 update Management of dyslipidemia  2019 update
Management of dyslipidemia 2019 update Moustafa Mokarrab
 

What's hot (20)

DELIVER delivered 2022.pptx
DELIVER delivered 2022.pptxDELIVER delivered 2022.pptx
DELIVER delivered 2022.pptx
 
Diabetic Dyslipidemia - A True CV risk
Diabetic Dyslipidemia - A True CV riskDiabetic Dyslipidemia - A True CV risk
Diabetic Dyslipidemia - A True CV risk
 
DYSLIPIDEMIA GUIDELINES
DYSLIPIDEMIA GUIDELINESDYSLIPIDEMIA GUIDELINES
DYSLIPIDEMIA GUIDELINES
 
Crestor Presentation
Crestor PresentationCrestor Presentation
Crestor Presentation
 
Antiplatelet therapy
Antiplatelet therapyAntiplatelet therapy
Antiplatelet therapy
 
Summary of PROVE-HF and GUIDE-IT studies by Dr. Vaibhav Yawalkar MD, DM Cardi...
Summary of PROVE-HF and GUIDE-IT studies by Dr. Vaibhav Yawalkar MD, DM Cardi...Summary of PROVE-HF and GUIDE-IT studies by Dr. Vaibhav Yawalkar MD, DM Cardi...
Summary of PROVE-HF and GUIDE-IT studies by Dr. Vaibhav Yawalkar MD, DM Cardi...
 
Lipid lowering trials ppt
Lipid lowering trials pptLipid lowering trials ppt
Lipid lowering trials ppt
 
Management of Dyslipidemia: role of Fenofibrate
Management of Dyslipidemia: role of FenofibrateManagement of Dyslipidemia: role of Fenofibrate
Management of Dyslipidemia: role of Fenofibrate
 
Statin combinations
Statin combinationsStatin combinations
Statin combinations
 
DYSLIPIDEMIA 2022.ppt
DYSLIPIDEMIA 2022.pptDYSLIPIDEMIA 2022.ppt
DYSLIPIDEMIA 2022.ppt
 
DAPT & Statin Fixed dose combination.pptx
DAPT & Statin Fixed dose combination.pptxDAPT & Statin Fixed dose combination.pptx
DAPT & Statin Fixed dose combination.pptx
 
New Treatments in HFrEF
New Treatments in HFrEFNew Treatments in HFrEF
New Treatments in HFrEF
 
ACC/AHA lipid guidelines 2018
ACC/AHA lipid guidelines 2018ACC/AHA lipid guidelines 2018
ACC/AHA lipid guidelines 2018
 
145pm-THREE-MAJOR-TRIALS-acc-2023.pdf
145pm-THREE-MAJOR-TRIALS-acc-2023.pdf145pm-THREE-MAJOR-TRIALS-acc-2023.pdf
145pm-THREE-MAJOR-TRIALS-acc-2023.pdf
 
Diabetic dyslipidemia
Diabetic dyslipidemiaDiabetic dyslipidemia
Diabetic dyslipidemia
 
Dyslipidemia GL & Total Vascular Benefit .pptx
Dyslipidemia GL & Total Vascular Benefit .pptxDyslipidemia GL & Total Vascular Benefit .pptx
Dyslipidemia GL & Total Vascular Benefit .pptx
 
Management of dyslipidemia 2019 update
Management of dyslipidemia  2019 update Management of dyslipidemia  2019 update
Management of dyslipidemia 2019 update
 
lipid guidelines.pptx
lipid guidelines.pptxlipid guidelines.pptx
lipid guidelines.pptx
 
Residual cardiovascular risk. We can do more!
Residual cardiovascular risk. We can do more!Residual cardiovascular risk. We can do more!
Residual cardiovascular risk. We can do more!
 
Ontarget
OntargetOntarget
Ontarget
 

Viewers also liked

2013 ACC/AHA guidelines for blood cholesterol management
2013 ACC/AHA guidelines for blood cholesterol management2013 ACC/AHA guidelines for blood cholesterol management
2013 ACC/AHA guidelines for blood cholesterol managementPraveen Nagula
 
Hyperlipidemia and drug therapy for hyperlipidemia
Hyperlipidemia and drug therapy for hyperlipidemiaHyperlipidemia and drug therapy for hyperlipidemia
Hyperlipidemia and drug therapy for hyperlipidemiaakbar siddiq
 
ATP IV Guideline for Blood cholesterol level
ATP IV Guideline for Blood cholesterol levelATP IV Guideline for Blood cholesterol level
ATP IV Guideline for Blood cholesterol levelkamalmodi481
 
2013 ACC/AHA LIPID GUIDELINES
2013 ACC/AHA LIPID GUIDELINES2013 ACC/AHA LIPID GUIDELINES
2013 ACC/AHA LIPID GUIDELINESSubhasish Deb
 
Atp 3 CHOLESTEROL GUIDELINES
Atp 3 CHOLESTEROL GUIDELINESAtp 3 CHOLESTEROL GUIDELINES
Atp 3 CHOLESTEROL GUIDELINESNaveen Kumar
 
Lipid management 2013 acc-aha guidelines
Lipid management   2013 acc-aha guidelinesLipid management   2013 acc-aha guidelines
Lipid management 2013 acc-aha guidelinesDr. Armaan Singh
 
Management of dyslipidemia
Management of dyslipidemiaManagement of dyslipidemia
Management of dyslipidemiaAmir Mahmoud
 
Blood test metrics interpretation cholesterol et al
Blood test metrics interpretation   cholesterol et alBlood test metrics interpretation   cholesterol et al
Blood test metrics interpretation cholesterol et alIvor Cummins
 
Basic Information About Cholesterol
Basic Information About CholesterolBasic Information About Cholesterol
Basic Information About Cholesterololiverdylan
 
Dyslipidemia management an evidence based approach
Dyslipidemia management an evidence based approachDyslipidemia management an evidence based approach
Dyslipidemia management an evidence based approachDr Vivek Baliga
 
Preventing Heart Disease - Statistics, Risk Factors and Prevention Guidelines
Preventing Heart Disease - Statistics, Risk Factors and Prevention GuidelinesPreventing Heart Disease - Statistics, Risk Factors and Prevention Guidelines
Preventing Heart Disease - Statistics, Risk Factors and Prevention GuidelinesMaps of World
 
How to protect our pregnant mothers from statins
How to protect our pregnant mothers from statinsHow to protect our pregnant mothers from statins
How to protect our pregnant mothers from statinsArnulfo Laniba
 
5 sexto mate
5 sexto mate5 sexto mate
5 sexto mateeduzzcom
 
Alternative angina therapy
Alternative angina therapyAlternative angina therapy
Alternative angina therapysaritadmcardio
 
http://www.youtube.com/watch?v=xrsHqIKtXNw
http://www.youtube.com/watch?v=xrsHqIKtXNwhttp://www.youtube.com/watch?v=xrsHqIKtXNw
http://www.youtube.com/watch?v=xrsHqIKtXNwIvor Cummins
 

Viewers also liked (20)

2013 ACC/AHA guidelines for blood cholesterol management
2013 ACC/AHA guidelines for blood cholesterol management2013 ACC/AHA guidelines for blood cholesterol management
2013 ACC/AHA guidelines for blood cholesterol management
 
Hyperlipidemia and drug therapy for hyperlipidemia
Hyperlipidemia and drug therapy for hyperlipidemiaHyperlipidemia and drug therapy for hyperlipidemia
Hyperlipidemia and drug therapy for hyperlipidemia
 
ATP IV Guideline for Blood cholesterol level
ATP IV Guideline for Blood cholesterol levelATP IV Guideline for Blood cholesterol level
ATP IV Guideline for Blood cholesterol level
 
2013 ACC/AHA LIPID GUIDELINES
2013 ACC/AHA LIPID GUIDELINES2013 ACC/AHA LIPID GUIDELINES
2013 ACC/AHA LIPID GUIDELINES
 
Atp 3 CHOLESTEROL GUIDELINES
Atp 3 CHOLESTEROL GUIDELINESAtp 3 CHOLESTEROL GUIDELINES
Atp 3 CHOLESTEROL GUIDELINES
 
Lipid management 2013 acc-aha guidelines
Lipid management   2013 acc-aha guidelinesLipid management   2013 acc-aha guidelines
Lipid management 2013 acc-aha guidelines
 
Management of dyslipidemia
Management of dyslipidemiaManagement of dyslipidemia
Management of dyslipidemia
 
Blood test metrics interpretation cholesterol et al
Blood test metrics interpretation   cholesterol et alBlood test metrics interpretation   cholesterol et al
Blood test metrics interpretation cholesterol et al
 
Basic Information About Cholesterol
Basic Information About CholesterolBasic Information About Cholesterol
Basic Information About Cholesterol
 
Dyslipidemia 2016
Dyslipidemia 2016Dyslipidemia 2016
Dyslipidemia 2016
 
Dyslipidemia management an evidence based approach
Dyslipidemia management an evidence based approachDyslipidemia management an evidence based approach
Dyslipidemia management an evidence based approach
 
Preventing Heart Disease - Statistics, Risk Factors and Prevention Guidelines
Preventing Heart Disease - Statistics, Risk Factors and Prevention GuidelinesPreventing Heart Disease - Statistics, Risk Factors and Prevention Guidelines
Preventing Heart Disease - Statistics, Risk Factors and Prevention Guidelines
 
Statin
StatinStatin
Statin
 
Cholesterol
CholesterolCholesterol
Cholesterol
 
Dyslipidemia
DyslipidemiaDyslipidemia
Dyslipidemia
 
How to protect our pregnant mothers from statins
How to protect our pregnant mothers from statinsHow to protect our pregnant mothers from statins
How to protect our pregnant mothers from statins
 
5 sexto mate
5 sexto mate5 sexto mate
5 sexto mate
 
Alternative angina therapy
Alternative angina therapyAlternative angina therapy
Alternative angina therapy
 
http://www.youtube.com/watch?v=xrsHqIKtXNw
http://www.youtube.com/watch?v=xrsHqIKtXNwhttp://www.youtube.com/watch?v=xrsHqIKtXNw
http://www.youtube.com/watch?v=xrsHqIKtXNw
 
Hypertryglycerdemia
HypertryglycerdemiaHypertryglycerdemia
Hypertryglycerdemia
 

Similar to Review of the New ACC/AHA Cholesterol Guidelines

2013 prevention guidelines cholesterol slide set 4
2013 prevention guidelines cholesterol slide set 42013 prevention guidelines cholesterol slide set 4
2013 prevention guidelines cholesterol slide set 4Sara Sirna
 
VIII reporte hipertension
VIII reporte hipertensionVIII reporte hipertension
VIII reporte hipertensionmelissalazaro1
 
Samir rafla jnc 8-2014 evidence-based guideline for the management of high bl...
Samir rafla jnc 8-2014 evidence-based guideline for the management of high bl...Samir rafla jnc 8-2014 evidence-based guideline for the management of high bl...
Samir rafla jnc 8-2014 evidence-based guideline for the management of high bl...Alexandria University, Egypt
 
Jnc 8 jama dic 2013
Jnc 8 jama dic 2013Jnc 8 jama dic 2013
Jnc 8 jama dic 2013raularnez2
 
Aos 213 01 nelson rivaroxaban effectiveness and safety in nvaf final
Aos 213 01 nelson rivaroxaban effectiveness and safety in nvaf finalAos 213 01 nelson rivaroxaban effectiveness and safety in nvaf final
Aos 213 01 nelson rivaroxaban effectiveness and safety in nvaf finalTrimed Media Group
 
EMR as a highly powerful European RWD source
EMR as a highly powerful European RWD sourceEMR as a highly powerful European RWD source
EMR as a highly powerful European RWD sourceIMSHealthRWES
 
Cancer and the General Internist
Cancer and the General InternistCancer and the General Internist
Cancer and the General InternistLanceCatedral
 
Evidence-Based Practice_Lecture 4_slides
Evidence-Based Practice_Lecture 4_slidesEvidence-Based Practice_Lecture 4_slides
Evidence-Based Practice_Lecture 4_slidesCMDLearning
 
APA-Schizophrenia-Clinical-Practice-Guidelines-Training-Slides.pptx
APA-Schizophrenia-Clinical-Practice-Guidelines-Training-Slides.pptxAPA-Schizophrenia-Clinical-Practice-Guidelines-Training-Slides.pptx
APA-Schizophrenia-Clinical-Practice-Guidelines-Training-Slides.pptxsameen51
 

Similar to Review of the New ACC/AHA Cholesterol Guidelines (20)

2013 prevention guidelines cholesterol slide set 4
2013 prevention guidelines cholesterol slide set 42013 prevention guidelines cholesterol slide set 4
2013 prevention guidelines cholesterol slide set 4
 
Jsc130010 jnc
Jsc130010  jncJsc130010  jnc
Jsc130010 jnc
 
ManejoJnc 8
ManejoJnc 8ManejoJnc 8
ManejoJnc 8
 
VIII reporte hipertension
VIII reporte hipertensionVIII reporte hipertension
VIII reporte hipertension
 
8 jnc
8 jnc8 jnc
8 jnc
 
Samir rafla jnc 8-2014 evidence-based guideline for the management of high bl...
Samir rafla jnc 8-2014 evidence-based guideline for the management of high bl...Samir rafla jnc 8-2014 evidence-based guideline for the management of high bl...
Samir rafla jnc 8-2014 evidence-based guideline for the management of high bl...
 
Jnc 8 jama dic 2013
Jnc 8 jama dic 2013Jnc 8 jama dic 2013
Jnc 8 jama dic 2013
 
Aos 213 01 nelson rivaroxaban effectiveness and safety in nvaf final
Aos 213 01 nelson rivaroxaban effectiveness and safety in nvaf finalAos 213 01 nelson rivaroxaban effectiveness and safety in nvaf final
Aos 213 01 nelson rivaroxaban effectiveness and safety in nvaf final
 
Jnc8
Jnc8Jnc8
Jnc8
 
EMR as a highly powerful European RWD source
EMR as a highly powerful European RWD sourceEMR as a highly powerful European RWD source
EMR as a highly powerful European RWD source
 
Impact of unhealthy behavior on per capita costs
Impact of unhealthy behavior on per capita costsImpact of unhealthy behavior on per capita costs
Impact of unhealthy behavior on per capita costs
 
Jnc viii
Jnc viiiJnc viii
Jnc viii
 
MyRISQ
MyRISQMyRISQ
MyRISQ
 
Cmaj.140703.full
Cmaj.140703.fullCmaj.140703.full
Cmaj.140703.full
 
Stress test
Stress testStress test
Stress test
 
Cancer and the General Internist
Cancer and the General InternistCancer and the General Internist
Cancer and the General Internist
 
AE poster
AE posterAE poster
AE poster
 
Evidence-Based Practice_Lecture 4_slides
Evidence-Based Practice_Lecture 4_slidesEvidence-Based Practice_Lecture 4_slides
Evidence-Based Practice_Lecture 4_slides
 
Nhanes ASCVD cost study
Nhanes ASCVD cost studyNhanes ASCVD cost study
Nhanes ASCVD cost study
 
APA-Schizophrenia-Clinical-Practice-Guidelines-Training-Slides.pptx
APA-Schizophrenia-Clinical-Practice-Guidelines-Training-Slides.pptxAPA-Schizophrenia-Clinical-Practice-Guidelines-Training-Slides.pptx
APA-Schizophrenia-Clinical-Practice-Guidelines-Training-Slides.pptx
 

More from Terry Shaneyfelt

Blinding in Clinical Trials
Blinding in Clinical TrialsBlinding in Clinical Trials
Blinding in Clinical TrialsTerry Shaneyfelt
 
Real vs rubbish ebm Evidence Live presentation april 2015
Real vs rubbish ebm  Evidence Live presentation april 2015Real vs rubbish ebm  Evidence Live presentation april 2015
Real vs rubbish ebm Evidence Live presentation april 2015Terry Shaneyfelt
 
Preoperative assessment of the older patient
Preoperative assessment of the older patientPreoperative assessment of the older patient
Preoperative assessment of the older patientTerry Shaneyfelt
 
UAB Pulmonary board review study design and statistical principles
UAB Pulmonary board review study  design and statistical principles UAB Pulmonary board review study  design and statistical principles
UAB Pulmonary board review study design and statistical principles Terry Shaneyfelt
 
Perioperative management of patients on corticosteroids
Perioperative management of patients on corticosteroidsPerioperative management of patients on corticosteroids
Perioperative management of patients on corticosteroidsTerry Shaneyfelt
 
Perioperative Management of Hypothyroid Patients Undergoing Nonthyroidal Surgery
Perioperative Management of Hypothyroid Patients Undergoing Nonthyroidal SurgeryPerioperative Management of Hypothyroid Patients Undergoing Nonthyroidal Surgery
Perioperative Management of Hypothyroid Patients Undergoing Nonthyroidal SurgeryTerry Shaneyfelt
 
Perioperative Diabetes Management in Patients on Insulin
Perioperative Diabetes Management in Patients on InsulinPerioperative Diabetes Management in Patients on Insulin
Perioperative Diabetes Management in Patients on InsulinTerry Shaneyfelt
 
Glycemia management in patients on oral agents
Glycemia management in patients on oral agentsGlycemia management in patients on oral agents
Glycemia management in patients on oral agentsTerry Shaneyfelt
 
Preoperative evaluation of patients with diabetes
Preoperative evaluation of patients with diabetesPreoperative evaluation of patients with diabetes
Preoperative evaluation of patients with diabetesTerry Shaneyfelt
 
What does an odds ratio or relative risk mean?
What does an odds ratio or relative risk mean? What does an odds ratio or relative risk mean?
What does an odds ratio or relative risk mean? Terry Shaneyfelt
 
Preoperative evaluation of adults with sleep apnea
Preoperative evaluation of adults with sleep apneaPreoperative evaluation of adults with sleep apnea
Preoperative evaluation of adults with sleep apneaTerry Shaneyfelt
 
Strategies to reduce postoperative pulmonary complications
Strategies to reduce postoperative pulmonary complicationsStrategies to reduce postoperative pulmonary complications
Strategies to reduce postoperative pulmonary complicationsTerry Shaneyfelt
 
Who needs preoperative pulmonary testing prior to noncardiothoracic surgery?
Who needs preoperative pulmonary testing prior to noncardiothoracic surgery?Who needs preoperative pulmonary testing prior to noncardiothoracic surgery?
Who needs preoperative pulmonary testing prior to noncardiothoracic surgery?Terry Shaneyfelt
 
Gupta indices for postop pulmonary complications
Gupta indices for postop pulmonary complicationsGupta indices for postop pulmonary complications
Gupta indices for postop pulmonary complicationsTerry Shaneyfelt
 
Procedure related risk factors for postop pulmonary complications
Procedure related risk factors for postop pulmonary complicationsProcedure related risk factors for postop pulmonary complications
Procedure related risk factors for postop pulmonary complicationsTerry Shaneyfelt
 
Patient related risk factors for postop pulmonary complications
Patient related risk factors for postop pulmonary complicationsPatient related risk factors for postop pulmonary complications
Patient related risk factors for postop pulmonary complicationsTerry Shaneyfelt
 
Noncardiac Surgery After PCI
Noncardiac Surgery After PCINoncardiac Surgery After PCI
Noncardiac Surgery After PCITerry Shaneyfelt
 
Reducing Perioperative Cardiac Risk: Do Beta blockers Help?
Reducing Perioperative Cardiac Risk: Do Beta blockers Help?Reducing Perioperative Cardiac Risk: Do Beta blockers Help?
Reducing Perioperative Cardiac Risk: Do Beta blockers Help?Terry Shaneyfelt
 
Reducing perioperative cardiac complications: statins
Reducing perioperative cardiac complications: statinsReducing perioperative cardiac complications: statins
Reducing perioperative cardiac complications: statinsTerry Shaneyfelt
 

More from Terry Shaneyfelt (20)

Blinding in Clinical Trials
Blinding in Clinical TrialsBlinding in Clinical Trials
Blinding in Clinical Trials
 
Real vs rubbish ebm Evidence Live presentation april 2015
Real vs rubbish ebm  Evidence Live presentation april 2015Real vs rubbish ebm  Evidence Live presentation april 2015
Real vs rubbish ebm Evidence Live presentation april 2015
 
Hazard ratios
Hazard ratiosHazard ratios
Hazard ratios
 
Preoperative assessment of the older patient
Preoperative assessment of the older patientPreoperative assessment of the older patient
Preoperative assessment of the older patient
 
UAB Pulmonary board review study design and statistical principles
UAB Pulmonary board review study  design and statistical principles UAB Pulmonary board review study  design and statistical principles
UAB Pulmonary board review study design and statistical principles
 
Perioperative management of patients on corticosteroids
Perioperative management of patients on corticosteroidsPerioperative management of patients on corticosteroids
Perioperative management of patients on corticosteroids
 
Perioperative Management of Hypothyroid Patients Undergoing Nonthyroidal Surgery
Perioperative Management of Hypothyroid Patients Undergoing Nonthyroidal SurgeryPerioperative Management of Hypothyroid Patients Undergoing Nonthyroidal Surgery
Perioperative Management of Hypothyroid Patients Undergoing Nonthyroidal Surgery
 
Perioperative Diabetes Management in Patients on Insulin
Perioperative Diabetes Management in Patients on InsulinPerioperative Diabetes Management in Patients on Insulin
Perioperative Diabetes Management in Patients on Insulin
 
Glycemia management in patients on oral agents
Glycemia management in patients on oral agentsGlycemia management in patients on oral agents
Glycemia management in patients on oral agents
 
Preoperative evaluation of patients with diabetes
Preoperative evaluation of patients with diabetesPreoperative evaluation of patients with diabetes
Preoperative evaluation of patients with diabetes
 
What does an odds ratio or relative risk mean?
What does an odds ratio or relative risk mean? What does an odds ratio or relative risk mean?
What does an odds ratio or relative risk mean?
 
Preoperative evaluation of adults with sleep apnea
Preoperative evaluation of adults with sleep apneaPreoperative evaluation of adults with sleep apnea
Preoperative evaluation of adults with sleep apnea
 
Strategies to reduce postoperative pulmonary complications
Strategies to reduce postoperative pulmonary complicationsStrategies to reduce postoperative pulmonary complications
Strategies to reduce postoperative pulmonary complications
 
Who needs preoperative pulmonary testing prior to noncardiothoracic surgery?
Who needs preoperative pulmonary testing prior to noncardiothoracic surgery?Who needs preoperative pulmonary testing prior to noncardiothoracic surgery?
Who needs preoperative pulmonary testing prior to noncardiothoracic surgery?
 
Gupta indices for postop pulmonary complications
Gupta indices for postop pulmonary complicationsGupta indices for postop pulmonary complications
Gupta indices for postop pulmonary complications
 
Procedure related risk factors for postop pulmonary complications
Procedure related risk factors for postop pulmonary complicationsProcedure related risk factors for postop pulmonary complications
Procedure related risk factors for postop pulmonary complications
 
Patient related risk factors for postop pulmonary complications
Patient related risk factors for postop pulmonary complicationsPatient related risk factors for postop pulmonary complications
Patient related risk factors for postop pulmonary complications
 
Noncardiac Surgery After PCI
Noncardiac Surgery After PCINoncardiac Surgery After PCI
Noncardiac Surgery After PCI
 
Reducing Perioperative Cardiac Risk: Do Beta blockers Help?
Reducing Perioperative Cardiac Risk: Do Beta blockers Help?Reducing Perioperative Cardiac Risk: Do Beta blockers Help?
Reducing Perioperative Cardiac Risk: Do Beta blockers Help?
 
Reducing perioperative cardiac complications: statins
Reducing perioperative cardiac complications: statinsReducing perioperative cardiac complications: statins
Reducing perioperative cardiac complications: statins
 

Recently uploaded

The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?Ryan Addison
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu Medical University
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...bkling
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
Physiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisPhysiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisNilofarRasheed1
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 

Recently uploaded (20)

The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
Physiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisPhysiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid Arthritis
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
Cone beam CT: concepts and applications.pptx
Cone beam CT: concepts and applications.pptxCone beam CT: concepts and applications.pptx
Cone beam CT: concepts and applications.pptx
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 

Review of the New ACC/AHA Cholesterol Guidelines

  • 1. Update on the New ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults Terry Shaneyfelt, MD, MPH Gen Med Noon Conf. December 10, 2013
  • 2. Disclosures o > 5yrs ago speaker for unrestricted educational grant to Johns Hopkins School of Medicine on cholesterol mgmt and EBM • Funded by AstraZeneca (Rosuvastatin) o VA P&T Committee member
  • 3. Objectives o Apply the new guidelines to the care of adults at increased risk for ASCVD o Understand limitations of new pooled cohort risk prediction tool o Learn a little something about guideline limitations and prediction rules
  • 5. Clinical practice guidelines are statements that include recommendations intended to optimize patient care that are informed by a systematic review of evidence and an assessment of the benefits and harms of alternative care options -- Institute of Medicine 2011
  • 6. To be trustworthy guidelines must: o Be based on a systematic review of the existing evidence; o Be developed by a knowledgeable, multidisciplinary panel of experts and representatives from key affected groups; o Consider important patient subgroups and patient preferences, as appropriate; o Be based on an explicit and transparent process that minimizes distortions, biases, and conflicts of interest; o Provide a clear explanation of the logical relationships between alternative care options and health outcomes, o Provide ratings of both the quality of evidence and the strength of the recommendations; and o Be reconsidered and revised as appropriate when important new evidence warrants modifications of recommendations. IOM 2011
  • 7. o No LDL target o Statins only o Only considered high quality RCT data
  • 9. o ACS, h/o MI, angina, revascularization, TIA, stroke, peri pheral arterial disease o No RCTs identified that titrated drug therapy to specific LDL goals to improve ASCVD outcomes
  • 11. o Often genetic (family screening) o Consider secondary causes – Drugs (diuretics, cyclosporin, glucocorticoids, amiodaron e) – Biliary obstruction, nephrotic syndrome – Hypothyroidism, pregnancy* * Statins contraindicated in pregnancy & lactation
  • 12. o Extrapolation of data for primary prevention in high risk (≥ 7.5% 10 yr risk) who did not have diabetes – Expert opinion, some conflicting data (IIa, B) o < 40 or > 75 yrs the decision to initiate statin therapy should be individualized – Expert opinion, divergent opinions (IIa, C)
  • 13. o Most controversial area of guideline because of risk equations & lower cut off o Reasonable to offer statin therapy to those with risk of 5-7.5% [conflicting evidence (IIa, B)]
  • 14. Primary Prevention JAMA 11/25/13 o Healthy individuals aged 40-75 yrs., without serious comorbidities and who were not taking drugs with potential for statin interaction
  • 15. Primary Prevention o CTT metaanalysis (Lancet 2012;380:581) – Similar efficacy findings – found increased risk of myopathy (NNH 2000), diabetes (NNH 200) and hemorrhagic stroke (NNH 2000) – No reduction in CVD events in patients with • Heart failure • Maintenance hemodialysis
  • 17. o Conflicts of interest in most panel members o Increased in statin utilization (“statinization”)?
  • 18. Conflicts of Interest o 2 main types – Financial – Intellectual o Per IOM 2011: – Whenever possible GDG members should not have COIs. – Members with COIs should represent not more than a minority of the GDG. – The chair or co-chairs should not be a person(s) with COIs. – Funders should have no role in CPG development.
  • 19. Conflicts of Interest o COI should be disclosed • Disclosure should reflect all current and planned commercial (including services from which a clinician derives a substantial proportion of income), noncommercial, intellectual, institutional, and patient– public activities pertinent to the potential scope of the CPG. o Members of the GDG should divest themselves of financial investments they or their family members have in, and not participate in marketing activities or advisory boards of, entities whose interests could be affected by CPG recommendations
  • 20. “Majority of panelists on controversial new cholesterol guideline have current or recent ties to drug manufacturers” - BMJ 2013;347:16989 o Neil Stone, MD (chairman) • Abbott, AstraZeneca, Merck, Pfizer, Sanofi-Aventis and Schering-Plough • “I will not take industry funding for 2 years after release of the guidelines” o Jennifer Robinson, MD (Co-chair) • Financial ties to several statin manufactures while on panel from 2008-2013 o 6 of 8 panelist with financial ties during service on the panel!
  • 21. Conflicts of Interest o “Members with conflicts were asked to recuse themselves from voting on any aspect of the guideline where a conflict might exist” o Independent contractors performed the systematic review of evidence
  • 22. Increased in statin utilization (“statinization”)? o Risk calculator overestimates risk o Lower thresholds to initiate statin therapy o 101 million people in US aged 40-79 yrs without cardiovascular disease • 33 million expected to have ≥ 7.5% predicted risk • 13 million expected to have 5-7.4% predicted risk • US population 1/20th global population in this age range – (33+13) x 20 = 920 million worldwide would be new statin candidates (JAMA 12/2/13)
  • 23. Is this a bad thing? MI and stroke are leading causes of death in the US Health Affairs 2012
  • 24. o Risk prediction tool overestimates risk
  • 25. Clinical prediction rule development Step 2. Validation Evidence of reproducible accuracy Step 1. Derivation Identification of factors with predictive power Narrow Validation Application of a rule in a similar clinical setting and population as in Step 1 Broad Validation Application of a rule in multiple clinical settings with varying prevalence of disease Step 3. Impact Analysis Evidence that rule changes physician behavior and improves patient outcomes
  • 26. Why a new risk predictor? o Previously used Framingham risk score was not felt to be adequate because of its “derivation in an exclusively White sample population and the limited scope of the outcome (in determining CHD alone).” o Other risk scores also suffered from “nonrepresentative or historically dated populations, limited ethnic diversity, narrowly defined endpoints, endpoints influenced by provider preferences (e.g., revascularizations), and endpoints with poor reliability (e.g., angina and heart failure [HF]).” o Broader outcomes of interest • ASCVD: first occurrence of nonfatal myocardial infarction or CHD death, or fatal or nonfatal stroke
  • 28. Development of the Pooled Cohort Risk Assessment Equations – Used several large, racially and geographically diverse, modern NHLBI-sponsored cohort studies, including the ARIC study, Cardiovascular Health Study, and the CARDIA study, combined with applicable data from the Framingham Original and Offspring Study cohorts – Sex-and race-specific proportional hazards models that included the covariates of age, treated or untreated systolic blood pressure (SBP), total cholesterol, high-density lipoprotein cholesterol (HDLC), current smoking (Y/N), and diabetes (Y/N). – Calculated area under the receiver operating curve (Cstatistic) for discrimination and the calibration chi-squared statistic – External validation done in external cohorts consisting of Whites and African Americans from the Multi-Ethnic Study of Atherosclerosis (MESA) and the REasons for Geographic And Racial Differences in Stroke study (REGARDS) and contemporary cohorts from ARIC and Framingham.
  • 29. Validation o Discrimination – Accurately determine if a person has or doesn’t have disease – C-statistic or AUC o Calibration – How well do predicted risk estimates match observed risk in external populations
  • 30. Validation (http://circ.ahajournals.org/content/early/2013/11/11/01.cir.0000437741.48606.98/suppl/DC1 ) Wom en Algorithm Derivation Cohort Men Validation Cohorts Contemporary (4) MESA (5) Validation Cohorts Algorithm REGARDS (6) Derivation Cohort Contemporary (4) MESA (5) REGARDS (6) White Total N 11,240 6,509 1,273 6,333 9,098 5,041 1,184 5,296 Events(1) 683 400 37 101 1,032 539 57 218 Events(2) 722.9 426.7 38.4 120.7 1,095.2 580.9 59.7 250.2 Exp Events(3) 723.5 549.4 49.9 153.9 1,098.5 798.9 94.9 306.4 0.8058 0.7377 0.7109 0.6599 0.7462 0.6843 0.7044 0.5950 6.43 45.50 14.56 44.93 4.86 84.45 21.43 66.71 2,641 1,367 978 5,275 1,647 735 799 2,969 Events(1) 235 127 28 126 194 107 36 136 Events(2) 248.7 131.3 30.1 147.1 213.8 114.0 38.3 162.5 Exp Events(3) 250.6 173.5 59.4 217.5 212.5 120.8 72.3 180.7 0.8182 0.7068 0.7684 0.6625 0.7130 0.7109 0.6689 0.5564 7.25 15.96 18.51 48.22 6.71 12.62 24.40 46.23 Cstatistic Calib. Chi-sq African Am erican Total N Cstatistic Calib. Chi-sq C statistic: range 0.5 – 1.0 (“reasonable” > 0.7, “strong” > 0.8)
  • 32. External Validation The Lancet, Volume 382, Issue 9907, Pages 1762 - 1765 o How many of the 33 million expected to have risk >7.5% actually have risk that is much lower?
  • 33. What should you do about risk assessment? o Use the pooled risk estimation equations o Use other risk scores (eg Framingham, QRISK, etc) o Ignore any risk assessment and consider that almost everyone benefits from primary prevention o Use eligibility criteria of the primary prevention trials
  • 34. Other recommendations from the guidelines o In lower risk patients (5-7.5%, < 40 or > 75 yrs) clinicians should discuss with patients: • • • • ASCVD risk reduction benefits (30% RRR MIS, 45% HIS) Adverse effects (diabetes NNH 200) Drug-drug interactions Patient preferences o In lower risk individuals also consider: • FH of premature CAD (< 55yo M, < 65yo F) • hsCRP > 2 • CAC score >300 Agatston units (or >75 percentile for age)
  • 35. Other recommendations from the guidelines o CK should not be routinely measured o Measure baseline ALT and only remeasure if symptoms suggest hepatotoxicity o Screen for diabetes following current diabetes screening guidelines o Muscle symptoms: • Temporarily d/c statin and assess for rhabdo if severe & other conditions that cause muscle symptoms • Rechallenge with lower or same dose of statin – If statin causative then give lower dose of different statin
  • 36. Other recommendations from the guidelines o No recommendations for add-on therapy to lower LDL after optimal statin dosing o Separate guideline on triglycerides (Circul 2012) • No gemfibrozil • Fenofibrate only if TG > 500 mg/dl and benefits judged to outweigh risks o Consider rechecking lipid panel 4-12 wks after initiation to assess for adherence but not to adjust therapy
  • 39. Suggested Answers o Case 1: B • Pt has ASCVD and should be on high intensity statin o Case 2: A or B • Risk is estimated at 7.2% which is below absolute recommended cutoff to initiate statin therapy for primary prevention o Case 3: E (if not tolerated then D) • Risk is estimated at 9.1% (driven by age) which is above the 7.5% threshold.
  • 40. By Brian McFadden at DailyKos.com